BİLGİLER
| - 1981 | |
| English | |
| 0216 524 13 00 |
GÖREV ALDIĞI HASTANELER
- Hisar Hospital Intercontinental
Dr. Rahib Hasanov was born in 1981 in Azerbaijan. After completing his primary, secondary, and high school education there, he entered the medical profession by studying at Istanbul University Cerrahpaşa, English Medical Faculty from 1999 to 2005.
In 2006–2007, he participated in the Observership Program at Houston Methodist Hospital in Texas, USA, where he had the opportunity to work alongside leading physicians and witness advanced practices in modern medicine firsthand.
From 2009 to 2013, Dr. Hasanov completed his Internal Medicine residency at Istanbul University Cerrahpaşa Faculty of Medicine. He then pursued a subspecialty in Medical Oncology at Marmara University Faculty of Medicine between 2015 and 2018, deepening his scientific knowledge and clinical experience in oncology.
Throughout his career, Dr. Hasanov has attended numerous national and international congresses, seminars, and courses, keeping up with the latest developments in oncology. He has integrated modern treatment methods such as immunotherapies, targeted therapies, and smart drugs into his practice. With experience gained both in Turkey and abroad, he has developed a strong vision for individualized oncology care.
Dr. Hasanov has treated patients not only from Turkey but also from Azerbaijan, Montenegro, Georgia, Uzbekistan, and the Middle East, and regularly receives patients from Europe and the USA. He builds his medical practice on scientific advancement, ethical values, and a patient-centered approach, making him an internationally recognized and preferred oncology specialist.
Medical Interests
- Gastrointestinal System Tumors (Colon, Rectum, Stomach, Pancreas, Esophagus, Liver-Bile Ducts)
- Breast Cancers (Breast Cancer – Targeted Therapies)
- Lung Cancer (including Immunotherapies)
- Urogenital System Tumors (Prostate, Ovary, Endometrium, Cervix, Kidney)
- Subspecialty – Medical Oncology: Marmara University Faculty of Medicine, 2015–2018, Istanbul
- Specialty – Internal Medicine: Istanbul University Cerrahpaşa Faculty of Medicine, 2009–2013, Istanbul
- Medical Degree: Istanbul University Cerrahpaşa Faculty of Medicine, 1999–2005, Istanbul
- Observership Program: Houston Methodist Hospital, 2006–2007, Texas, USA
Professional Experience
- Acıbadem Altunizade Private Hospital – Medical Oncology Specialist | 2020–2025, Istanbul
- EMSEY Private Hospital – Medical Oncology Specialist | 2018–2020, Istanbul
- Kolan Private Hospital – Internal Medicine Specialist | 2013–2015, Istanbul
- Gastrointestinal System Tumors (Colon, Rectum, Stomach, Pancreas, Esophagus, Liver-Bile Ducts)
- Breast Cancer (Targeted Therapies)
- Lung Cancer (including Immunotherapies)
- Urogenital System Tumors (Prostate, Ovary, Endometrium, Cervix, Kidney)
- Information to be added
- Akin Telli T, Ozturk MA, Alan O, Hasanov R, et al. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy. Future Oncol. 2022 Jul;18(22):2425-2439. doi: 10.2217/fon-2021-1322.
- Alan O, Akin Telli T, Aktas B, Ökten IN, Hasanov R, et al. Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment? World J Surg Oncol. 2020 Sep 9;18(1):242. doi: 10.1186/s12957-020-02019-y.
- Demirelli B, Babacan NA, Ercelep Ö, Hasanov R, et al. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer. Nutr Cancer. 2021;73(2):230-238. doi: 10.1080/01635581.2020.1749290.
- Alan O, Akin Telli T, Ercelep O, Hasanov R, et al. Chordoma: a case series and review of the literature. J Med Case Rep. 2018 Aug 27;12(1):239. doi: 10.1186/s13256-018-1784-y.
- Alan O, Telli TA, Ercelep O, Hasanov R, et al. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy. Curr Probl Cancer. 2019 Aug;43(4):308-311. doi: 10.1016/j.currproblcancer.2018.04.003.
- Kaya S, Hasanov R, et al. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer. J BUON. 2017 Sep-Oct;22(5):1191-1198.
